Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06842667 · ClinicalTrials.gov registry record · NA
Development and Preliminary Testing of a "Papageno"-Story Interview Intervention- Aim 3
A NA study, sponsored by University of Michigan.
- Completed
- Registry status
- NA
- Development phase
- 506
- Enrollment target
NCT06842667: Completed NA study, sponsored by University of Michigan.
NCT06842667 is a NA study that has completed, run by University of Michigan. The registered enrollment target is 506 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (64% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06842667, a NA study, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- NA
- Development phase
- 506 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effects of a short "Papageno story" video of a compilation of interviews on proximal risk factors for suicide. The researchers believe that the intervention may increase protective factors related to suicide.
Primary Outcome
Assessed with the Abbreviated Reasons For Living- Young Adult Abbreviated (RFL-YA-II) which consists of 24 questions rated on a scale of 1-6. Higher scores indicate greater importance.
Interventions
- BEHAVIORAL Control video
- BEHAVIORAL Papageno video
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 506 participants |
| Start Date | 2025-09-17 |
| Est. Completion | 2025-10-06 |
| Phase | NA |
What the finished NCT06842667 record still lists
NCT06842667 is an interventional study that assigns participants to a tested intervention. The registered 506 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (64% lower).
The record links to 0 conditions, and to 2 interventions - of which Control video is the first listed.
NCT06842667 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06842667 about?
NCT06842667 is a clinical study titled "Development and Preliminary Testing of a "Papageno"-Story Interview Intervention- Aim 3". The purpose of this study is to determine the effects of a short "Papageno story" video of a compilation of interviews on proximal risk factors for suicide. The researchers believe that the intervention may increase protective factors related to suicide.
What is the current status of trial NCT06842667?
This trial is currently completed. It is a NA study. The enrollment target is 506 participants. The study started on 2025-09-17. Estimated completion is 2025-10-06.
What interventions are being tested in trial NCT06842667?
The interventions under investigation include: Control video (BEHAVIORAL), Papageno video (BEHAVIORAL).
Who is sponsoring clinical trial NCT06842667?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06842667's enrollment target sits among peer trials
506 193rd of 2000 higher than 1,808 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05069428 · 506 participants · Phase 4
Delirium Reduction With Ramelteon
- NCT05797168 · 506 participants · Phase 1
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
- NCT06164717 · 507 participants · NA
Behavioral and Neural Characteristics of Adaptive Speech Motor Control
- NCT02115295 · 508 participants · Phase 2
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI